Login Register Cart 0
Generic placeholder image

Applied Drug Research, Clinical Trials and Regulatory Affairs

Editor-in-Chief

ISSN (Print): 2667-3371
ISSN (Online): 2667-338X

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Artificial Intelligence in Drug Regulatory Submissions in India

Author(s): Vikesh Kumar Shukla* and Manvi Kumar Mittal

Volume 9, Issue 1, 2022

Published on: 02 March, 2023

Article ID: e090223213556 Pages: 11

DOI: 10.2174/2667337109666230209152153

Price: $65

conference banner
Abstract

Regulatory affairs are one of the most crucial connections between the pharmaceutical company and the other stakeholder’s or regulatory agencies such as FDA, EMA, etc. Strategies in drug approval and marketing to assure the quality, safety, and efficacy of the drug follow the guidelines and laws stated under the drug and cosmetic act 1940 and rules 1945. Their primary responsibility is to keep the company in compliance with changing guidelines, which necessitates constant monitoring of the most recent industry updates. Drug regulation is a complex process as every country has its own set of documentation that must be done while regulatory submissions. From drug development and drug approval to drug commercialisation, there is a large amount of documentation that must be completed with accuracy, which can be challenging for the professional to complete, therefore, this leads to the introduction of the concept of big data that can be incorporated which will map the regulations according to 5vs model of big data. Thus, to make it more efficient, we can work big data with artificial intelligence to ease the process using natural language processing. This concept will map all the rules and guidelines together and make a cluster of similar rules together. Now, users can use the tool to locate the data of interest in a single site in a more comprised universal language that can be accessed by any professional to complete the task in the given time schedule.

[1]
Laenen K. The key role of regulatory affairs in the pharmaceutical industry: From drug development to commercialization, QbD Group. 2023. Available from: https://qbdgroup.com/en/blog/thekey- role-of-regulatory-affairs-in-the-pharmaceutical-industryfrom- drug-development-tocommercialization/#:~: text=Regulatory%20Affairs%20plays%20a%20crucial%2 0role%20in%20the,development%2C%20and%20even%20after% 20drug%20approval%20and%20commercialization
[2]
ICH M4/The Common Technical Document (CTD): Comparison of Clinical Documents and Summaries Assessment Practices in the United States, Europe, and Japan. 2022. Available from: https://journals.sagepub.com/doi/10.1177/009286159903300230
[3]
Aher R, Aher P, Ahire T, Shahare HV, Nemade CT. Regulatory requirement and step for registration and approval of Indian drug products in overseas market. Int J Pharm Sci Rev Res 2021; 68(2): 54-62.
[http://dx.doi.org/10.47583/ijpsrr.2021.v68i02.009]
[4]
Johnson T, Joyner M, DePourcq F, et al. et al. Using Research Metrics to Improve Timelines Proceedings from the 2nd Annual CTSA Clinical Research Management Workshop. Clin translat Sci 3(6): 305-8.
[5]
Evangeline L, Mounica NV, Reddy VS, Ngabhushanam MV, Reddy DN, Bonthagarala B. Regulatory process and ethics for clinical trials in India (CDSCO). Pharma Innov 2017; 6(4, Part C): 165.
[6]
How ‘big data’ is different - harvard business school Available from: https://www.hbs.edu/ris/Publication%20Files/SMR-How-Big-Data-Is-Different_782ad61f-8e5f-4b1e-b79f-83f33c903455.pdf
[7]
Pittsburgh A. Challenges and opportunities with Big Data. Proceedings VLDB Endowment 2012; 5(12): 2032-3.
[8]
Oussous A, Benjelloun FZ, Lahcen AA, Belfkih S. Big Data technologies A survey. J King Saud Univ - Comput Inf Sci 2017; S1319-1578(17): 30003-4..
[9]
Sagiroglu S, Sinanc D. Big data: A review. 2013 International Conference on Collaboration Technologies and Systems (CTS) San Diego, CA, USA. 2013; pp. 42-7. Available from: https://ieeexplore.ieee.org/document/6567202
[10]
George G, Haas MR, Pentland A. Big data and management. Acad Manage J 2014; 57(2): 321-6.
[http://dx.doi.org/10.5465/amj.2014.4002]
[11]
Fionda B, Boldrini L, D’Aviero A, et al. Artificial intelligence (AI) and interventional radiotherapy (brachytherapy): State of art and future perspectives. J Contemp Brachytherapy 2020; 12(5): 497-500.
[http://dx.doi.org/10.5114/jcb.2020.100384] [PMID: 33299440]
[12]
Artificial Intelligence: A modern approach. Available from: http://aima.cs.berkeley.edu/
[13]
Luger GF. Artificial Intelligence: Structures and strategies for complex problem solving. 2011. Available from: https://books.google.com/books/about/Artificial_Intelligence.html?id=qScrAAAAQBAJ
[14]
Lee JG, Kang M. Geospatial big data: Challenges and opportunities. Big Data Research 2015; 2(2): 74-81.
[http://dx.doi.org/10.1016/j.bdr.2015.01.003]
[15]
Brexit impact on the European pharmaceutical mark 2022. Available from: https://www.linkedin.com/pulse/brexit-impact-european-pharmaceutical-market-sebastian-gensior?articleId=6423502770166390784
[16]
Narang JK, Dogra A, Ali J, Baboota S, Singh H. Drug regulatory affairs: An introduction. In: Regulatory Affairs in the Pharmaceutical Industry. Cambridge, Massachusetts: Academic Press 2022; pp. 1-30.
[http://dx.doi.org/10.1016/B978-0-12-822211-9.00001-0]
[17]
Gupta S, Baboota S, Ali J, Dang S. Regulatory affairs for chemistry, manufacturing, and controls Regulatory Affairs in the Pharmaceutical Industry. Cambridge, Massachusetts: Academic Press 2022; pp. 75-87.
[http://dx.doi.org/10.1016/B978-0-12-822211-9.00003-4]
[18]
Bangarurajan K. Regulatory process for new drug approval in India.In: Drug Discovery and Development. Singapore: Springer 2021; pp. 451-63.
[19]
Senthil V, Baviya Priyadharshini R, Ramachandran A, Ganesh GN, Shrivastava A. Regulatory process for import and export of drugs in India. Int J Pharm Sci Res 2015.
[20]
Khan MA, Shafi S, Ahmad SS, Ahmed F. Regulatory affairs in clinical trials.In: Regulatory Affairs in the Pharmaceutical Industry. Cambridge, Massachusetts: Academic Press 2022; pp. 241-61.
[http://dx.doi.org/10.1016/B978-0-12-822211-9.00006-X]
[21]
Williams CT. Food and drug administration drug approval process: A history and overview. Nurs Clin North Am 2016; 51(1): 1-11.
[22]
DiMasi JA. The value of improving the productivity of the drug development process: Faster times and better decisions. PharmacoEconomics 2002; 20(3) (Suppl. 3): 1-10.
[http://dx.doi.org/10.2165/00019053-200220003-00001] [PMID: 12457421]
[23]
Food and Drug Administration HHS. Abbreviated New Drug Applications and 505(b)(2) Applications. Final rule. Fed Regist 2016; 81(194): 69580-658.
[PMID: 27731961]
[24]
Basak A, Raw A, Alhakim A, et al. Pharmaceutical impurities: Regulatory perspective for abbreviated new drug applications. Adv Drug Deliv Rev 2007; 59(1): 64-72.
[http://dx.doi.org/10.1016/j.addr.2006.10.010] [PMID: 17196703]
[25]
Fan J, Han F, Liu H. Challenges of big data analysis. Natl Sci Rev 2014; 1(2): 293-314.
[http://dx.doi.org/10.1093/nsr/nwt032] [PMID: 25419469]
[26]
Tole AA. Big data challenges. Database systems journal 2013; 4(3): 31-40.
[27]
Ishwarappa AnuradhaJ. A brief introduction on Big Data 5Vs characteristics and Hadoop technology. Procedia Comput Sci 2015; 48: 319-24.
[http://dx.doi.org/10.1016/j.procs.2015.04.188]
[28]
Peddireddy AS, Xie D, Patil P, et al. From 5vs to 6cs: Operationalizing epidemic data management with covid-19 surveillance. In IEEE International Conference on Big Data (Big Data). 1380: 7.
[29]
Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. Trends Pharmacol Sci 2019; 40(8): 577-91.
[http://dx.doi.org/10.1016/j.tips.2019.05.005] [PMID: 31326235]
[30]
Angus DC. Randomized clinical trials of artificial intelligence. JAMA 2020; 323(11): 1043-5.
[http://dx.doi.org/10.1001/jama.2020.1039] [PMID: 32065828]
[31]
Dong J, Geng Y, Lu D, et al. Clinical trials for artificial intelligence in cancer diagnosis: A cross-sectional study of registered trials in ClinicalTrials. gov. Front Oncol 2020; 10: 1629.
[http://dx.doi.org/10.3389/fonc.2020.01629] [PMID: 33042806]
[32]
Ramesh AN, Kambhampati C, Monson JRT, Drew PJ. Artificial intelligence in medicine. Ann R Coll Surg Engl 2004; 86(5): 334-8.
[http://dx.doi.org/10.1308/147870804290] [PMID: 15333167]
[33]
Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today 2021; 26(1): 80-93.
[http://dx.doi.org/10.1016/j.drudis.2020.10.010] [PMID: 33099022]
[34]
Basile AO, Yahi A, Tatonetti NP. Artificial intelligence for drug toxicity and safety. Trends Pharmacol Sci 2019; 40(9): 624-35.
[http://dx.doi.org/10.1016/j.tips.2019.07.005] [PMID: 31383376]
[35]
Mehr H, Ash H, Fellow D. Artificial intelligence for citizen services and government. Ash Cent Democr Gov Innov Harvard Kennedy Sch 2017; (August): 1-2.
[36]
Attia ZI, Friedman PA, Noseworthy PA, et al. Age and sex estimation using artificial intelligence from standard 12-lead ecgs. CirculationArrhythmia and electrophysiology 2019; 12(9): e007284.
[37]
Sparck Jones K. Information retrieval and artificial intelligence. Artif Intell 1999; 114(1-2): 257-81.
[http://dx.doi.org/10.1016/S0004-3702(99)00075-2]
[38]
Khozin S, Kim G, Pazdur R. From big data to smart data: FDA’s INFORMED initiative. Nat Rev Drug Discov 2017; 16(5): 306-7.
[http://dx.doi.org/10.1038/nrd.2017.26] [PMID: 28232724]
[39]
Elezabeth L, Mishra VP, Dsouza J. “The Role of Big Data Mining in Healthcare Applications,” 2018 7th International Conference on Reliability, Infocom Technologies and Optimization (Trends and Future Directions) (ICRITO), Noida, India 2018 2018; 256-60.
[http://dx.doi.org/10.1109/ICRITO.2018.8748434]
[40]
Chowdhary KR. Fundamentals of Artificial Intelligence Available from: https://link.springer.com/book/10.1007/978-81-322-3972-7
[41]
Nadkarni PM, Ohno-Machado L, Chapman WW. Natural language processing: An introduction. J Am Med Inform Assoc 2011; 18(5): 544-51.
[http://dx.doi.org/10.1136/amiajnl-2011-000464] [PMID: 21846786]
[42]
Hirschberg J, Manning CD. Advances in natural language processing. Science 2015; 349(6245): 261-6.
[http://dx.doi.org/10.1126/science.aaa8685] [PMID: 26185244]
[43]
Townsend H. Natural language processing and clinical outcomes: the promise and progress of NLP for improved care. J AHIMA 2013; 84(3): 44-5.
[PMID: 23556403]
[44]
Lewis DD, Jones KS. Natural language processing for information retrieval. Commun ACM 1996; 39(1): 92-101.
[http://dx.doi.org/10.1145/234173.234210]
[45]
Luo Y, Thompson WK, Herr TM, et al. Natural language processing for EHR-based pharmacovigilance: A structured review. Drug Saf 2017; 40(11): 1075-89.
[http://dx.doi.org/10.1007/s40264-017-0558-6] [PMID: 28643174]
[46]
Haris SS, Omar N. "A rule-based approach in Bloom's Taxonomy question classification through natural language processing," 2012 7th International Conference on Computing and Convergence Technology (ICCCT), Seoul, Korea (South), 2012; pp. 410-4. [https://ieeexplore.ieee.org/document/6530368
[47]
Bao Y, Deng Z, Wang Y, et al. Using machine learning and natural language processing to review and classify the medical literature on cancer susceptibility genes. JCO Clin Cancer Inform 2019; 3: 1-9.
[48]
Friedman C, Shagina L, Lussier Y, Hripcsak G. Automated encoding of clinical documents based on natural language processing. J Am Med Inform Assoc 2004; 11(5): 392-402.
[http://dx.doi.org/10.1197/jamia.M1552] [PMID: 15187068]
[49]
Chodorow M, Dickinson M, Israel R, Tetreault J. Problems in evaluating grammatical error detection systems. Proceedings of COLING. 611-28.
[50]
Sanderson A. Importance of drug regulations, Tablet Presses LFA Machines. Available from 2019. [https://www.lfatabletpresses.com/articles/drug-regulations-importance
[51]
Home Available from: https://cdsco.gov.in/opencms/opencms/en/Home
[52]
Ghooi R. Expert committee to formulate policy and guidelines for approval of new drugs, clinical trials and banning of drugs-comments. Perspect Clin Res 2014; 5(3): 100-7.
[http://dx.doi.org/10.4103/2229-3485.134304] [PMID: 24987579]
[53]
Center for Drug Evaluation and Research. New Drug Application (NDA), U.S. Food and Drug Administration. Available from: https://www.fda.gov/drugs/types-applications/new-drug-application-nda
[54]
Jia A, Xu L, Wang Y. Venn diagrams in bioinformatics. Brief Bioinform 2021; 22(5): bbab108.
[http://dx.doi.org/10.1093/bib/bbab108] [PMID: 33839742]
[55]
Lin S. The present and future of Team Documentation: The role of patients, families, and Artificial Intelligence. Available from 2020. [https://www.mayoclinicproceedings.org/article/S0025-6196(20)30134-8/fulltext
[56]
A review of artificial intelligence algorithms in document classification Available from: https://www.researchgate.net/publication/260096292_A_Review_of_Artificial_Intelligence_Algorithms_in_Document_Classification
[57]
Management of the document preparation process. Available from: https://conservationtools.org/guides/104-management-of-the-document-preparation-process

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy